EUVIMEDEUVIMED entdecken
Open Access

Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma

Matthew J Rees, Timothy T Xu, Suheil Albert Atallah-Yunes, Kenneth J C Lim, Sikander Ailawadhi, Ricardo Parrondo, Rafael Fonseca, Peter Leif Bergsagel, Suzanne Hayman, Angela Dispenzieri, Francis Buadi, David Dingli und 10 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026

DOI: 10.1016/j.clml.2025.10.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Matthew J Rees und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, MN. Electronic address: Rees.Matthew@mayo.edu. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunoconjugates, B-Cell Maturation Antigen, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Paula and Rodger Riney Foundation, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Uptake of BCMA-directed antibody drug conjugates (ADCs) in multiple myeloma has been hindered by ocular side-effects. Belantamab mafodotin (BelMaf) and MEDI2228 are BCMA-directed monoclonal-antibodies conjugated to the microtubule inhibitor, monomethyl auristatin F and the alkylator, pyrrolobenzodiazepine, respectively. Differences in ADC payload, antibody specificity and linker stability influence ocular toxicity. AIM/METHODS: We investigated the tolerability and ocular toxicity profiles of BCMA-directed ADC therapy. Retrospective study of 111 patients treated with BCMA-directed ADCs between 2019 and 2022. RESULTS: Eighty-seven percent of patients were triple-class refractory, 50% penta-class refractory, 14% had prior BCMA-directed therapy and 24% extraosseous disease. Treatments included BelMaf monotherapy (n = 56), BelMaf combination therapy (n = 12) and MEDI2228 monotherapy (n = 43). The overall response rate was 30% for BelMaf and 44% for MEDI2228. Photophobia was more common with MEDI2228 (any-grade: 12% vs. 49%, P < .001), whereas keratopathy was more common with BelMaf (any-grade: 59% vs. 9%, P = .002). Four MEDI2228 recipients developed keratopathy, all grade 1 and associated with dry eyes and/or photophobia. Dose delay for ocular toxicity was comparable for BelMaf and MEDI2228 (28% vs. 19%, P = 0.2), as was the rate of dose reduction (18% vs. 12%, P = .4). The most common reasons for treatment discontinuation were progression/death (BelMaf = 71%, MEDI2228 = 44%) and ocular toxicity (BelMaf = 18%, MEDI2228 = 30%). CONCLUSIONS: Treatment interruptions, dose reductions and drug discontinuation are common with BCMA-directed ADC therapy. Research to optimize the administration schedule of these agents is warranted. BelMaf and MEDI2228 produce distinct patterns of ocular side-effects, namely keratopathy and reduced visual-acuity with the former, and photophobia and dry eyes with the latter.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunoconjugatesB-Cell Maturation AntigenAntibodies, Monoclonal, HumanizedHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAged, 80 and overAdult

Stichwörter der Autor:innen

Adverse effectsB-cell maturation antigenDose modificationKeratopathyMonoclonal gammopathy

Substanzen

ImmunoconjugatesB-Cell Maturation Antigenbelantamab mafodotinAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, MN. Electronic address: Rees.Matthew@mayo.edu.
  • Division of Ophthalmology, Mayo Clinic, Rochester, MN.
  • Division of Hematology, Mayo Clinic, Rochester, MN.
  • Division of Hematology, Mayo Clinic, Jacksonville, FL.
  • Division of Hematology, Mayo Clinic, Phoenix, AZ.

Förderung

  • NCI NIH HHS
  • Paula and Rodger Riney Foundation
  • National Cancer Institute
  • Mayo Clinic
  • National Institutes of Health

Zitieren

APA

Rees, M. J., Xu, T. T., Atallah-Yunes, S. A., Lim, K. J. C., Ailawadhi, S., Parrondo, R., Fonseca, R., Bergsagel, P. L., Hayman, S., Dispenzieri, A., Buadi, F., Dingli, D., Warsame, R., Kapoor, P., Abeykoon, J. P., Gertz, M. A., Muchtar, E., Kourelis, T., Gonsalves, W., …, & Kumar, S. (2026). Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.10.003

Vancouver

Rees MJ, Xu TT, Atallah-Yunes SA, Lim KJC, Ailawadhi S, Parrondo R, et al. Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2025.10.003

BibTeX
@article{Rees2026,
  author = {Rees, Matthew J and Xu, Timothy T and Atallah-Yunes, Suheil Albert and Lim, Kenneth J C and Ailawadhi, Sikander and Parrondo, Ricardo and Fonseca, Rafael and Bergsagel, Peter Leif and Hayman, Suzanne and Dispenzieri, Angela and Buadi, Francis and Dingli, David and Warsame, Rahma and Kapoor, Prashant and Abeykoon, Jithma P and Gertz, Morie A and Muchtar, Eli and Kourelis, Taxiarchis and Gonsalves, Wilson and Rajkumar, S Vincent and Patel, Sanjay V and Kumar, Shaji},
  title = {Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2025.10.003}
}
Kostenlos starten →